Sentences with phrase «cancer research program now»

In the early 1990s, the group lobbied to create a Department of Defense breast cancer research program now funded at $ 150 million a year.

Not exact matches

University of Calgary researchers including Luchman, Weiss and Dr. Greg Cairncross — director of SACRI, and leader of the Terry Fox Research Institute (TFRI) «Therapeutic Targeting of Glioblastoma research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliobResearch Institute (TFRI) «Therapeutic Targeting of Glioblastoma research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliobresearch program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblprogram at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblacancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblaCancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblProgram), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblastoma.

Its founder, Allan Bradley, was at the time based at the M.D. Anderson Cancer Research Center in Houston, Texas, and now heads the world's largest mouse genetics program at the Wellcome Trust Sanger Institute, which has a strong cancer compCancer Research Center in Houston, Texas, and now heads the world's largest mouse genetics program at the Wellcome Trust Sanger Institute, which has a strong cancer compcancer component.

NIH supports both innovation and «optimization that can benefit patients — such as making a cancer drug less toxic or more potent,» says Andilibi, now program director of the US National Cancer Institute's Small Business Innovation Research (SBIR) Development Center in Bethesda, Marcancer drug less toxic or more potent,» says Andilibi, now program director of the US National Cancer Institute's Small Business Innovation Research (SBIR) Development Center in Bethesda, MarCancer Institute's Small Business Innovation Research (SBIR) Development Center in Bethesda, Maryland.

«Until now, physicians have taken a «wait and see» approach to antiviral therapies following transplantation,» says Toor, a hematologist - oncologist in the Bone Marrow Transplant Program and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of MeProgram and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Meprogram at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine.

«We are at a point in our research where we have validated the efficacy of this combination treatment approach in preclinical animal models, and we now need to define its safety through toxicology and pharmacology studies,» says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Mresearch where we have validated the efficacy of this combination treatment approach in preclinical animal models, and we now need to define its safety through toxicology and pharmacology studies,» says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular MResearch and co-leader of the Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Mresearch program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine.

Harari, Coukos and their colleagues will now be applying their findings to an ambitious program to develop and streamline personalized immunotherapies for cancer patients currently underway at the Lausanne Branch of the Ludwig Institute for Cancer Rescancer patients currently underway at the Lausanne Branch of the Ludwig Institute for Cancer ResCancer Research.

The effort is now led by Dr. Parvesh Kumar, UNLV School of Medicine senior associate dean for clinical research and cancer program director.

Complementing these research efforts are those of the Cancer Immunotherapy Consortium (CIC), which is now a program of the Cancer Research Inresearch efforts are those of the Cancer Immunotherapy Consortium (CIC), which is now a program of the Cancer Research InResearch Institute.

Angela K. Green, MD, MSc, formerly of the UNC Lineberger's Cancer Outcomes Research Program and the UNC School of Medicine who is now at the Memorial Sloan Kettering Cancer Center, was also a co-author of the viewpoint.

Now in its ninth year, the campaign focuses on helping families pay for pet cancer treatment and funds innovative research programs.

We work every day to help kids with cancer through funding research looking for new treatments and by funding programs that help families are kids that are sick now.